Literature DB >> 25556333

Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai Women's Health Study.

Zhezhou Huang1,2, Yutang Gao3, Wanqing Wen2, Honglan Li3, Wei Zheng2, Xiao-Ou Shu2, Alicia Beeghly-Fadiel2.   

Abstract

Oral contraceptive use is associated with reduced ovarian cancer risk; however, associations with other contraceptive methods, such as intrauterine device (IUD) and tubal ligation, are less clear. Women in China differ from western women in regard to mechanisms and duration of use of contraception. This study was undertaken to evaluate associations between contraceptive methods and ovarian cancer risk using data from the prospective Shanghai Women's Health Study. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by Cox proportional hazards regression. A total of 174 epithelial ovarian cancer cases were found to occur among 70,259 women who were followed-up for a total of 888,258 person-years. The majority of women had ever used any contraception (77.0%), including IUD (55.6%), oral contraceptive (20.4%), tubal ligation (14.7%) or contraceptive shots (2.6%). Ever use of any contraception was associated with a nonsignificant reduction in ovarian cancer risk (HR: 0.86, 95% CI: 0.60-1.24). Longer duration of IUD use was associated with lower ovarian cancer risk (p-value for trend = 0.04). Compared with never users, women with durations of IUD use longer than the median (20 years) were 38% less likely to develop ovarian cancer (HR: 0.62, 95% CI: 0.40-0.97). Based on the high prevalence and long duration of IUD use among Chinese women, we estimate a preventive fraction of 9.3%, corresponding to approximately 16 ovarian cancer cases. High prevalence of long-term IUD use may, therefore, contribute to the low incidence of ovarian cancer observed in China.
© 2014 UICC.

Entities:  

Keywords:  contraceptive; ovarian cancer risk; prospective cohort study

Mesh:

Year:  2015        PMID: 25556333      PMCID: PMC4437849          DOI: 10.1002/ijc.29412

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

1.  [Influence factors in etiology of epithelial ovarian cancer].

Authors:  G Zhang; S Jiang; F Zhang
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  1996-06

2.  Regional economic levels and adverse events linked to intrauterine devices.

Authors:  Gao Zhan; Li Ling; Li Ying; You-ping Li; Wen Jin; Wang Li
Journal:  J Evid Based Med       Date:  2011-02

Review 3.  The role of the fallopian tube in the origin of ovarian cancer.

Authors:  Britt K Erickson; Michael G Conner; Charles N Landen
Journal:  Am J Obstet Gynecol       Date:  2013-04-10       Impact factor: 8.661

Review 4.  The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Authors:  Christopher P Crum; Ronny Drapkin; Alexander Miron; Tan A Ince; Michael Muto; David W Kindelberger; Yonghee Lee
Journal:  Curr Opin Obstet Gynecol       Date:  2007-02       Impact factor: 1.927

5.  The cost of IUD failure in China.

Authors:  J Kaufman
Journal:  Stud Fam Plann       Date:  1993 May-Jun

6.  The Shanghai Women's Health Study: rationale, study design, and baseline characteristics.

Authors:  Wei Zheng; Wong-Ho Chow; Gong Yang; Fan Jin; Nathaniel Rothman; Aaron Blair; Hong-Lan Li; Wanqing Wen; Bu-Tian Ji; Qi Li; Xiao-Ou Shu; Yu-Tang Gao
Journal:  Am J Epidemiol       Date:  2005-10-19       Impact factor: 4.897

7.  Type of intrauterine device and the risk of pelvic inflammatory disease.

Authors:  N C Lee; G L Rubin; H W Ory; R T Burkman
Journal:  Obstet Gynecol       Date:  1983-07       Impact factor: 7.661

8.  Events of reproductive life and the incidence of epithelial ovarian cancer.

Authors:  H A Risch; N S Weiss; J L Lyon; J R Daling; J M Liff
Journal:  Am J Epidemiol       Date:  1983-02       Impact factor: 4.897

9.  Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.

Authors:  Weiva Sieh; Shannon Salvador; Valerie McGuire; Rachel Palmieri Weber; Kathryn L Terry; Mary Anne Rossing; Harvey Risch; Anna H Wu; Penelope M Webb; Kirsten Moysich; Jennifer A Doherty; Anna Felberg; Dianne Miller; Susan J Jordan; Marc T Goodman; Galina Lurie; Jenny Chang-Claude; Anja Rudolph; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Elisa V Bandera; Sara H Olson; Melony G King; Lorna Rodriguez-Rodriguez; Lambertus A Kiemeney; Tamara Marees; Leon F Massuger; Anne M van Altena; Roberta B Ness; Daniel W Cramer; Malcolm C Pike; Celeste Leigh Pearce; Andrew Berchuck; Joellen M Schildkraut; Alice S Whittemore
Journal:  Int J Epidemiol       Date:  2013-04       Impact factor: 7.196

10.  Reproductive factors in relation to ovarian cancer: a case-control study in Northern Vietnam.

Authors:  Duc-Cuong Le; Tatsuhiko Kubo; Yoshihisa Fujino; David C Sokal; Trinh Huu Vach; Truong-Minh Pham; Shinya Matsuda
Journal:  Contraception       Date:  2012-05-11       Impact factor: 3.375

View more
  14 in total

1.  Urinary PGE-M Levels and Risk of Ovarian Cancer.

Authors:  Mollie E Barnard; Alicia Beeghly-Fadiel; Ginger L Milne; Eftitan Y Akam; Andrew T Chan; A Heather Eliassen; Bernard A Rosner; Xiao-Ou Shu; Kathryn L Terry; Yong-Bing Xiang; Wei Zheng; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-06       Impact factor: 4.254

Review 2.  The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence.

Authors:  R Troisi; T Bjørge; M Gissler; T Grotmol; C M Kitahara; S M Myrtveit Saether; A G Ording; C Sköld; H T Sørensen; B Trabert; I Glimelius
Journal:  J Intern Med       Date:  2018-03-25       Impact factor: 8.989

Review 3.  Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer.

Authors:  William V Williams; Louise A Mitchell; S Kathleen Carlson; Kathleen M Raviele
Journal:  Linacre Q       Date:  2019-01-03

4.  Intrauterine device use and risk of ovarian cancer: Results from the New England Case-Control study and Nurses' Health Studies.

Authors:  Jiaxi Yang; Naoko Sasamoto; Ana Babic; Allison F Vitonis; Mary K Townsend; Linda Titus; Daniel W Cramer; Shelley S Tworoger; Kathryn L Terry
Journal:  Int J Cancer       Date:  2021-03-17       Impact factor: 7.316

5.  The Association between Endometriosis, Tubal Ligation, Hysterectomy and Epithelial Ovarian Cancer: Meta-Analyses.

Authors:  Chunpeng Wang; Zhenzhen Liang; Xin Liu; Qian Zhang; Shuang Li
Journal:  Int J Environ Res Public Health       Date:  2016-11-14       Impact factor: 3.390

6.  Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.

Authors:  Minh Tung Phung; Alice W Lee; Anna H Wu; Andrew Berchuck; Kathleen R Cho; Daniel W Cramer; Jennifer Anne Doherty; Marc T Goodman; Gillian E Hanley; Holly R Harris; Karen McLean; Francesmary Modugno; Kirsten B Moysich; Bhramar Mukherjee; Joellen M Schildkraut; Kathryn L Terry; Linda J Titus; Susan J Jordan; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02-22       Impact factor: 4.090

7.  Gene expression profiling of ovarian carcinomas and prognostic analysis of outcome.

Authors:  Sheng-Yun Cai; Tian Yang; Yu Chen; Jing-Wen Wang; Li Li; Ming-Juan Xu
Journal:  J Ovarian Res       Date:  2015-07-31       Impact factor: 4.234

Review 8.  Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management.

Authors:  Anna L Beavis; Anna Jo Bodurtha Smith; Amanda Nickles Fader
Journal:  Int J Womens Health       Date:  2016-05-23

9.  Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium.

Authors:  Tomotaka Ugai; Linda E Kelemen; Mika Mizuno; Jue-Sheng Ong; Penelope M Webb; Georgia Chenevix-Trench; Kristine G Wicklund; Jennifer Anne Doherty; Mary Anne Rossing; Pamela J Thompson; Lynne R Wilkens; Michael E Carney; Marc T Goodman; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Hui Cai; Xiao-Ou Shu; Yu-Tang Gao; Yong-Bing Xiang; David Van Den Berg; Malcom C Pike; Anna H Wu; Celeste Leigh Pearce; Keitaro Matsuo
Journal:  Cancer Sci       Date:  2018-01-21       Impact factor: 6.716

Review 10.  A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).

Authors:  Luca Falzone; Giuseppa Scandurra; Valentina Lombardo; Giuseppe Gattuso; Alessandro Lavoro; Andrea Benedetto Distefano; Giuseppe Scibilia; Paolo Scollo
Journal:  Int J Oncol       Date:  2021-06-16       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.